These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24330467)

  • 1. Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.
    Petrongari MG; Landoni V; Saracino B; Gomellini S; Arcangeli S; Iaccarino G; Pinnarò P; Arcangeli G; Strigari L
    J Exp Clin Cancer Res; 2013 Dec; 32(1):103. PubMed ID: 24330467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
    Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience.
    Detti B; Baki M; Becherini C; Saieva C; Scartoni D; Giacomelli I; Trombetta L; Muntoni C; Olmetto E; Francolini G; Turkaj A; Topulli J; Ciabatti C; Carta G; Poggesi L; Delli Paoli C; Terziani F; Grassi R; Livi L
    Radiol Med; 2019 May; 124(5):422-431. PubMed ID: 30607866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
    Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
    Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.
    Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity.
    Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N
    Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
    Liauw SL; Weichselbaum RR; Rash C; Correa D; Al-Hallaq HA; Pelizzari CA; Jani AB
    Technol Cancer Res Treat; 2009 Jun; 8(3):201-6. PubMed ID: 19445537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity.
    Zilli T; Rouzaud M; Jorcano S; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escude L; Molla M; Linero D; Weber DC; Miralbell R
    Technol Cancer Res Treat; 2010 Jun; 9(3):263-70. PubMed ID: 20441236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
    Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.
    Guckenberger M; Ok S; Polat B; Sweeney RA; Flentje M
    Strahlenther Onkol; 2010 Oct; 186(10):535-43. PubMed ID: 20890743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
    Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
    In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
    Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
    Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.